Découvrir
Liste des blocs
Texte

Dernière mise à jour le 18 juin 2021

bc-GenExMiner

Texte
  • Intérêt de l’outil web bc-GenExMiner en oncologie. Jézéquel P, Gouraud W, Ben Azzouz F, Basseville A, Juin PP, Lasla H, Campone M. Bull Cancer 2021; accepté, en cours de publication.
  • bc-GenExMiner 4.5: new mining module computes breast cancer gene expression differential analyses. Jézéquel P, Gouraud W, Ben Azzouz F, Guérin-Charbonnel C, Lasla H, Campone M. DataBase (Oxford) 2021;2021:baab007.
  • bc-GenExMiner 3.0: new mining module computes breast cancer gene-expression correlation analyses. Jézéquel P, Frénel JS, Campion L, Guérin-Charbonnel C, Gouraud W, Ricolleau G, Campone M. Database 2013;bas060.
  • bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer. Jézéquel P, Campone M, Gouraud W, Charbonnel C, Leux C, Ricolleau G, Campion L. Breast Cancer Res Treat 2012;131:765-775.

Sous-typage TNBC

Texte

Détermination de classe

  • Identification of three subtypes of triple negative breast cancer with potential therapeutic implications. Jézéquel P, Kerdraon O, Hondermarck H, Guérin-Charbonnel C, Lasla H, Gouraud G, Canon JL, Gombos A, Dalenc F, Delaloge S, Lemonnier J, Loussouarn D, Verrièle V, Campone M. Breast Cancer Res 2019;21:65.
  • iTRAQ-based quantitative proteomic analysis strengthens transcriptomic subtyping of triple-negative breast cancer tumors. Jézéquel P, Guette C, Lasla H, Gouraud W, Boissard A, Guérin-Charbonnel C, Campone M. Proteomics 2019;e1800484.
  • Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response. Jézéquel P, Loussouarn D, Guérin-Charbonnel C, Campion L, Vanier A, Gouraud W, Hamza L, Guette C, Valo I, Verrièle V, Campone M. Breast Cancer Res 2015; 17:43.

Prédiction de classe

  • Development of an absolute assignment predictor for triple-negative breast cancer subtyping using machine learning approaches. Ben Azzouz F, Michel B, Lasla H, Gouraud W, François AF, Girka F, Lecointre T, Guérin-Charbonnel C, Juin PP, Campone M, Jézéquel P. Comput Biol Med 2021;129:104171.

EPICURE sein méta

Texte
  • A partial graphical model with a structural prior on the direct links between predictors and responses. Okomé-Obiang E, Jézéquel P, Proïa F. ESAIM Probab Stat 2021; accepté, en cours de publication.
  • The EPICURE study: a pilot prospective cohort study of integration of heterogeneous data in metastatic breast cancer patients. Colombié M, Jézéquel P, Rubeaux M, Frénel JS, Seegers V, Campone M. BMC Cancer 2021;21:333.  
  • Automatic segmentation of metastatic breast cancer lesions on 18F-FDG PET/CT longitudinal acquisitions for treatment response assessment. Moreau N, Rousseau C, Fourcade C, Santini G, Brennan A, Ferrer L, Lacombe M, Guillerminet C, Colombié M, Jézéquel P, Campone M, Normand N, Rubeaux M. Cancers (Basel) 2021;14:101.

Divers

Texte

Transcriptomique.

  • Lohard S, Bourgeois N, Maillet L, Gautier F, Fétiveau A, Lasla H, Nguyen F, Vuillier C, Dumont A, Moreau-Aubry A, Frapin M, David L, Loussouarn D, Kerdraon O, Campone M, Jézéquel P, Juin PP, Barillé-Nion S. STING-dependent paracriny shapes apoptotic priming of breast tumors in response to anti-mitotic treatment. Nature Comm 2020;11:259
  • Gene-expression signature functional annotation of breast cancer tumours in function of age. Jézéquel P, Sharif Z, Lasla H, Gouraud W, Guérin-Charbonnel C, Campion L, Chrétien S, Campone M. BMC Med Genomics 2015;8:80.
  • Early dynamic transcriptomic changes during preoperative radiotherapy in patients with rectal cancer: a feasibility study. Supiot S, Gouraud W, Campion L, Jézéquel P, Buecher B, Charrier J, Heymann MF, Mahé MA, Rio E, Chérel M. World J Gastroenterol 2013; 19: 3249-3254.
  • Molecular characterization of the response to chemotherapy in conventional osteosarcomas: predictive value of HSD17B10 and IFITM2. Salas S, Jézéquel P, Campion L, Chibon F, Bartoli C, Charbonnel C, Gouraud W, Porsche B, Gentet JC, Bollini G, Rochwerger A, Duffaud F, Figarella-Branger D, Bouvier C. Int J Cancer 2009; 125: 851-860.
  • A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial. Jézéquel P, Campone M, Roché H, Gouraud W, Charbonnel C, Ricolleau G, Magrangeas F, Minvielle S, Genève J, Martin AL, Bataille R, Campion L. Breast Cancer Res Treat 2009; 116: 509-520.
  • Prediction of survival in multiple myeloma based on gene-expression profiles revealed cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients. Decaux O, Lodé L, Magrangeas F, Charbonnel C, Gouraud W, Jézéquel P, Attal M, Harousseau JL, Moreau P, Bataille R, Campion L, Avet-Loiseau H, Minvielle S, on behalf of the Intergroupe Francophone du Myélome (2008) J Clin Oncol 2008; 26: 4798-4805.
  • Prediction of metastatic relapse in node-positive breast cancer: establishment of a clinicogenomic model after FEC100 adjuvant regimen. Campone M, Campion L, Roché H, Gouraud W, Charbonnel C, Magrangeas F, Minvielle S, Genève J, Martin AL, Bataille R, Jézéquel P. Breast Cancer Res Treat 2008; 109: 491-501.
  • Gene expression profiles discriminate between pathologic complete response and resistance to neoadjuvant FEC100 in breast cancer. Millour M, Charbonnel C, Magrangeas F, Minvielle S, Campion L, Gouraud W, Campone M, Déporte-Féty R, Bignon YJ, Penault-Llorca F, Jézéquel P. Cancer Genomics and Proteomics 2006; 3: 89-96.

Protéomique

  • Identification of potential prognostic biomarkers for node-negative breast cancer tumours by proteomic analysis: a multicentric 2004 national PHRC study. International Descotes F, Jézéquel P, Spyratos F, Campion L, Grenot C, Lerebours F, Campone M, Guérin-Charbonnel C, Lanoë D, Adams M, André J, Carlioz A, Martin PM, Chassevent A, Jourdan ML, Guette C, Zanella-Cleon I, Ricolleau G. J Oncol 2012; 41: 92-104.
  • Validation of tumor-associated macrophage ferritin light chain as a prognostic biomarker in node-negative breast cancer tumors: a multicentric 2004 national PHRC study. Jézéquel P, Campion L, Spyratos F, Loussouarn D, Campone M, Guérin-Charbonnel C, Joalland MP, André J, Descotes F, Grenot C, Roy P, Carlioz A, Martin PM,  Chassevent A, Jourdan ML, Ricolleau G. Int J Cancer 2012; 131: 426-437.
  • Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors. Ricolleau G, Charbonnel C, Lodé L, Loussouarn D, Joalland MP, Jourdain S, Minvielle S, Campone M, Déporte-Féty R, Campion L, Jézéquel P. Proteomics 2006; 6.06: 1963-1975.

Radiomique 

  • Prognostic value of metabolic, volumetric and textural parameters of baseline [18F]FDG PET/CT in early triple-negative breast cancer. Bouron C, Mathie C , Seegers V, Morel O, Jézéquel P, Lasla H, Guillerminet C, Girault S, Lacombe M, Sher A, Lacoeuille F, Patsouris A, Testard A. Cancers (Basel) 2022;14:637.

Data Science

  • Random forest of perfect trees: concepts, performances, applications and perspectives. Nguyen JM, Jézéquel P, Gillois P, Silva L, Lambert-Lacroix S, Juin P, Campone M, Gaultier A, Moreau-Gaudry A, Antonioli D. Bioinformatics 2021;btab074.

Collaborations

Texte

Transcriptomique

  • The SigmaR1 chaperone drives breast and colorectal cancer cell migration by tuning SK3-depedent Ca2+ homeostasis. Gueguinou M, Crottès D, Chantôme A, Rapetti-Mauss R, Potier-Cartereau M, Clarysse L, Girault A, Fourbon Y, Jézéquel P, Guérin-Charbonnel C, Fromont G, Martin P, Pellissier B, Schiappa R, Chamorey E, Mignen O, Uguen A, Borgese F, Vandier C, Soriani O. Oncogene 2017;36 :3640-3647.
  • p53 deficiency induces cancer stem cell pool expansion in a mouse model of triple-negative breast tumors. Chiche A, Moumen M, Romagnoli M, Petit V, Lasla H, Jézéquel P, de la Grange P, Jonkers J, Deugnier MA, Glukhova MA, Faraldo MM. Oncogene 2016;36 :2355-2365.
  • Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Le Tourneau CL, Delord JP, Gonçalves A, Gavoille C, Dubot C, Isambert N, Campone M, Trédan O, Massiani MA, Mauborgne C, Armanet S, Servant N, Bièche I, Bernard V, Gentien D, Jézéquel P, Attignon V, Boyault S, Vincent-Salomon A, Servois V, Sablin MP, Kamal M, Paoletti X; SHIVA investigators. Lancet Oncol 2015;16 :1324-1334.